RxDoctor Payments DataLook up a doctor →

Fielding Johnson, MD

Pulmonary Disease · East Hartford, CTNPI 1346336237

Payments from drug & device makers

$30,602in general payments, 2019–2025

Across 1,072 payments — averaging $28.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$5K
  • AstraZeneca$3K
  • Amgen$2K
  • AbbVie$2K
  • Boehringer Ingelheim$2K
  • Mallinckrodt Hospital Products Inc.$2K
  • plus $15K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK121$4,833
AstraZeneca(2 entities)104$2,737
Amgen73$1,998
AbbVie(2 entities)62$1,903
Boehringer Ingelheim73$1,638
Mallinckrodt Hospital Products Inc.44$1,630
Abbott63$1,347
Lilly USA, LLC70$1,282
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)17$1,221
Sanofi-aventis U.S. LLC43$791
Corcept Therapeutics25$669
Actelion Pharmaceuticals US, Inc.9$610
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC22$589
Regeneron Healthcare Solutions, Inc.12$557
Johnson & Johnson19$516
Mylan Specialty L.p.13$430
Pfizer18$399
E.r. Squibb & Sons, L.L.C.5$392
Novartis14$380
Harmony Biosciences LLC10$320
Otsuka America Pharmaceutical, Inc.10$311
Novo Nordisk16$286
Takeda Pharmaceuticals U.S.A., Inc.11$284
Neurocrine Biosciences, Inc.3$280
Amarin Pharma, Inc.8$255
Endo Pharmaceuticals Inc.15$249
Lifescan, Inc.16$244
Daiichi Sankyo Inc.8$243
Sunovion Pharmaceuticals Inc.7$218
Amneal Pharmaceuticals LLC10$213
Grifols USA, LLC10$210
Sanofi2$198
Pulmonx Corporation2$181
Phathom Pharmaceuticals, Inc.3$159
Bayer6$148
Viatris Specialty LLC3$147
Cequr Corporation1$141
Exact Sciences5$140
Antares Pharma, Inc.2$140
Astellas Pharma US Inc7$139
Dexcom, Inc.6$132
Shire North American Group Inc7$131
Travere Therapeutics, Inc.1$127
Axsome Therapeutics, Inc.2$127
Radius Health, Inc.6$117
Merck7$103
Xeris Pharmaceuticals, Inc.5$90
Ultragenyx Pharmaceutical Inc.4$73
IBSA Pharma Inc.4$73
Amryt Pharma Holdings Ltd4$72
Advanced Respiratory, Inc3$64
Verona Pharma, Inc.3$63
Alvogen Inc3$59
Lundbeck LLC3$55
Mallinckrodt Enterprises LLC3$54
Electromed, Inc.5$54
Kyowa Kirin, Inc.3$52
Eisai Inc.3$48
BD3$47
Mannkind Corporation1$44

How this compares

$30,602 in reported general payments places this provider in the 85th percentile of 255 pulmonary disease providers in Connecticut.

See all pulmonary disease providers in Connecticut →

Medicare billing

Part B allowed, 2024
$33,593
Medicare patients
89
Services billed
343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pulmonary disease in East Hartford

See the full list for Connecticut →

Where these figures come from

Is this you, or does something look wrong? →